Capital Management Corp VA Increases Holdings in Lifevantage Corporation $LFVN

Key Points

• Capital Management Corp VA increased its stake in Lifevantage Corporation by 77.0% during Q2, now owning over 1.26 million shares valued at approximately $16.56 million.
• Lifevantage's recent quarterly earnings met analyst expectations with an EPS of $0.17, but its revenue fell short of forecasts at $55.11 million.
• Despite receiving mixed analyst ratings, Lifevantage has declared a $0.045 quarterly dividend, reflecting a 2.0% yield with a payout ratio of 24.32%.

Capital Management Corp VA increased its stake in Lifevantage Corporation (NASDAQ:LFVN - Free Report) by 77.0% during the second quarter, according to its most recent filing with the SEC. The fund owned 1,266,110 shares of the company's stock after buying an additional 550,607 shares during the quarter. Lifevantage accounts for approximately 2.8% of Capital Management Corp VA's portfolio, making the stock its 14th largest holding. Capital Management Corp VA owned 10.06% of Lifevantage worth $16,561,000 as of its most recent SEC filing.

A number of other large investors have also added to or reduced their stakes in the stock. Farther Finance Advisors LLC bought a new stake in Lifevantage in the second quarter worth about $25,000. Goldman Sachs Group Inc. raised its holdings in shares of Lifevantage by 24.5% in the 1st quarter. Goldman Sachs Group Inc. now owns 44,518 shares of the company's stock worth $649,000 after purchasing an additional 8,762 shares during the period. Acadian Asset Management LLC lifted its stake in Lifevantage by 47.3% in the first quarter. Acadian Asset Management LLC now owns 291,700 shares of the company's stock valued at $4,248,000 after purchasing an additional 93,661 shares during the last quarter. Jane Street Group LLC grew its holdings in Lifevantage by 5.4% during the first quarter. Jane Street Group LLC now owns 36,567 shares of the company's stock valued at $533,000 after purchasing an additional 1,877 shares during the period. Finally, Jones Financial Companies Lllp grew its holdings in Lifevantage by 14,484.0% during the first quarter. Jones Financial Companies Lllp now owns 29,168 shares of the company's stock valued at $425,000 after purchasing an additional 28,968 shares during the period. Hedge funds and other institutional investors own 35.32% of the company's stock.

Lifevantage Stock Performance

Shares of LFVN opened at $9.04 on Wednesday. Lifevantage Corporation has a 52-week low of $8.80 and a 52-week high of $27.38. The stock's 50-day simple moving average is $11.60 and its 200 day simple moving average is $12.52. The stock has a market capitalization of $114.72 million, a price-to-earnings ratio of 12.22 and a beta of 0.26.

Lifevantage (NASDAQ:LFVN - Get Free Report) last announced its quarterly earnings results on Thursday, September 4th. The company reported $0.17 earnings per share for the quarter, meeting the consensus estimate of $0.17. Lifevantage had a return on equity of 33.75% and a net margin of 4.29%.The firm had revenue of $55.11 million for the quarter, compared to analysts' expectations of $57.93 million. During the same period in the prior year, the business posted $0.14 earnings per share. Lifevantage has set its FY 2026 guidance at 1.000-1.15 EPS.

Lifevantage Dividend Announcement

The company also recently declared a quarterly dividend, which was paid on Tuesday, September 16th. Stockholders of record on Monday, September 8th were given a dividend of $0.045 per share. This represents a $0.18 dividend on an annualized basis and a dividend yield of 2.0%. The ex-dividend date was Monday, September 8th. Lifevantage's payout ratio is 24.32%.

Analyst Upgrades and Downgrades

Several analysts have issued reports on the company. Wall Street Zen lowered Lifevantage from a "buy" rating to a "hold" rating in a research note on Friday, October 3rd. Weiss Ratings reissued a "hold (c+)" rating on shares of Lifevantage in a report on Wednesday, October 8th. Two analysts have rated the stock with a Buy rating and one has given a Hold rating to the company's stock. According to data from MarketBeat, the company has an average rating of "Moderate Buy" and a consensus price target of $30.50.

Insiders Place Their Bets

In other Lifevantage news, Director Michael A. Beindorff sold 4,125 shares of the firm's stock in a transaction dated Tuesday, September 9th. The stock was sold at an average price of $11.44, for a total value of $47,190.00. Following the sale, the director owned 22,858 shares of the company's stock, valued at $261,495.52. This trade represents a 15.29% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this link. 21.95% of the stock is owned by corporate insiders.

Lifevantage Company Profile

LifeVantage Corporation engages in the identification, research, development, formulation, and sale of advanced nutrigenomic activators, dietary supplements, nootropics, pre- and pro-biotics, weight management, skin and hair care, bath and body, and targeted relief products. It offers Protandim, a dietary supplement; LifeVantage Omega+, a dietary supplement that combines DHA and EPA Omega-3 fatty acids, Omega-7 fatty acids, and vitamin D3; LifeVantage ProBio, a dietary supplement to support gut health; PhysIQ, a weight management system; LifeVantage IC Bright, a supplement to support eye and brain health, reduce eye fatigue and strain, supports cognitive functions, and support normal sleep patterns; Petandim for Dogs, a supplement to combat oxidative stress in dogs; and Axio, a nootropic energy drink mix.

Want to see what other hedge funds are holding LFVN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Lifevantage Corporation (NASDAQ:LFVN - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.